The copy number variation of GSTM1 as a promising prognostic factor of oral squamous cell carcinoma
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
CURIONI, Otavio A.
ANTONIO, Juliana De
Citação
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, v.134, n.5, p.615-626, 2022
Resumo
Objective. The aim of this study was to investigate whether the copy number variation (CNV) of GSTM1 and GSTT1 is related to the occurrence of oral squamous cell carcinoma (OSCC) relapses, along the overall and progression-free survival of patients. Study Design. A total of 234 OSCC patients were recruited from the Heliopolis hospital and they were distributed among 4 groups according to the occurrence of OSCC relapses. Fisher exact test, odds ratio (OR), and 95% CI were determined to investigate the chances of OSCC progression. The overall and progression-free survival were analyzed by the Kaplan-Meier and Cox regression methods. Results. The CNV of GSTM1 analysis showed that one copy of the gene was associated with reduced chances of OSCC recurrences (OR 0.45; 95% CI 0.25-0.81) and decreased the risk of tumor progression (HR 0.50; 95% CI 0.33-0.75). Furthermore, one copy of GSTM1 was related to a better overall survival rate (HR 0.63; 95% CI 0.0.44-0.91). Regarding the CNV of GSTT1, no copies were associated with the chances of OSCC relapses, the overall survival, or the progression-free survival. Conclusions. The CNV of GSTM1 may be applied to predict OSCC relapses and aid the treatment management, which might improve the survival rates of patients.
Palavras-chave
Referências
- Aires FT, 2017, ORL J OTO-RHINO-LARY, V79, P347, DOI 10.1159/000485627
- Almal SH, 2012, J HUM GENET, V57, P6, DOI 10.1038/jhg.2011.108
- Ambrosone CB, 2001, CANCER RES, V61, P7130
- Anantharaman D, 2007, CARCINOGENESIS, V28, P1455, DOI 10.1093/carcin/bgm038
- Brasch-Andersen C, 2004, HUM MUTAT, V24, P208, DOI 10.1002/humu.20074
- Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
- Carta A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081563
- Choudhari SK, 2014, ORAL ONCOL, V50, P10, DOI 10.1016/j.oraloncology.2013.09.011
- Costa A, 2014, SEMIN CANCER BIOL, V25, P23, DOI 10.1016/j.semcancer.2013.12.007
- Curioni OA, 2013, J CANC THER, V4, P978
- Drummond SN, 2004, ORAL ONCOL, V40, P52, DOI 10.1016/S1368-8375(03)00132-5
- Drummond SN, 2005, ORAL ONCOL, V41, P515, DOI 10.1016/j.oraloncology.2004.12.014
- Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
- Gkouveris I, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317711659
- Gleber-Netto FO, 2015, ORAL ONCOL, V51, P738, DOI 10.1016/j.oraloncology.2015.04.016
- Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
- He QF, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22403
- Hosni A, 2019, RADIOTHER ONCOL, V134, P10, DOI 10.1016/j.radonc.2019.01.014
- Hung RJ, 2004, INT J CANCER, V110, P598, DOI 10.1002/ijc.20157
- Katakwar P, 2016, J CANCER RES THER, V12, P438, DOI 10.4103/0973-1482.151935
- Kim D, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0631-8
- Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
- Li SL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0792-3
- MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
- Muddathir ARM, 2019, BOSNIAN J BASIC MED, V19, P350, DOI 10.17305/bjbms.2019.4176
- Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229
- Rhodus Nelson L, 2014, Dent Clin North Am, V58, P315, DOI 10.1016/j.cden.2013.12.004
- Olivieri EHR, 2009, ORAL ONCOL, V45, pE73, DOI 10.1016/j.oraloncology.2009.03.004
- Rivera C, 2015, INT J CLIN EXP PATHO, V8, P11884
- Rockville U.S. Department of Health and Human Services, 2010, CHEM TOX CIG SMOK BI
- Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171
- Safi AF, 2017, J CRANIO MAXILL SURG, V45, P1749, DOI 10.1016/j.jcms.2017.07.012
- Sardaro N, 2019, IN VIVO, V33, P289, DOI 10.21873/invivo.11474
- Sato M, 2000, ORAL ONCOL, V36, P267, DOI 10.1016/S1368-8375(99)00090-1
- Sekikawa S, 2020, J ORAL MAXIL SURG, V78, P469, DOI 10.1016/j.joms.2019.10.018
- Singh S, 2015, CANCER CHEMOTH PHARM, V75, P1, DOI 10.1007/s00280-014-2566-x
- Speleman F, 2008, CYTOGENET GENOME RES, V123, P176, DOI 10.1159/000184706
- Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130
- Sudmant PH, 2015, SCIENCE, V349, DOI 10.1126/science.aab3761
- Taningher M, 1999, MUTAT RES-REV MUTAT, V436, P227, DOI 10.1016/S1383-5742(99)00005-8
- Troeltzsch M, 2018, J ORAL MAXIL SURG, V76, P2650, DOI 10.1016/j.joms.2018.07.005
- Trueba GP, 2004, FRONT BIOSCI-LANDMRK, V9, P2029, DOI 10.2741/1335
- Weckx A, 2019, ORAL ONCOL, V94, P8, DOI 10.1016/j.oraloncology.2019.05.002
- Xu CJ, 2005, ARCH PHARM RES, V28, P249, DOI 10.1007/BF02977789
- Yanamoto S, 2012, INT J ORAL MAX SURG, V41, P1195, DOI 10.1016/j.ijom.2012.07.011
- Zarrei M, 2015, NAT REV GENET, V16, P172, DOI 10.1038/nrg3871
- Zhang XM, 2013, PHARMACOGEN PERS MED, V6, P9, DOI 10.2147/PGPM.S35949